Supplements

The review reported statistically significant reductions in systolic blood pressure with vitamin C and combined vitamin C plus E, and an HDL cholesterol increase with the combination. These results concern measured risk markers in diabetes. Significant findings for some approaches alone do not establish differences between approaches or show fewer clinical complications.

Keep in mind: The abstract omits doses, treatment durations, control details, effect sizes and confidence intervals. It also describes systolic blood pressure effects as both comparable and differing, leaving the comparison unclear.

Personalized vitamin D supplementation reduced a blood marker of inflammation in this specific group of patients after colorectal cancer surgery. The abstract does not establish better cancer control, survival, or recovery. Its result concerns a laboratory measurement, and changes in the other measured markers were not statistically significant.

Keep in mind: The abstract reports a short trial focused on inflammatory biomarkers. It gives no cancer outcome or adverse-event results, so this abstract-based summary cannot establish clinical benefit or safety.

Vitamin D supplementation did not clearly reduce new physician-diagnosed major depression during the planned treatment period in older adults who were largely vitamin D sufficient. Longer follow-up produced a borderline signal in the higher-dose group, but it does not establish a delayed benefit or show that one dose worked better than the other.

Keep in mind: This abstract-based summary is limited by few depression events and broad confidence intervals. Participants were largely vitamin D sufficient, limiting conclusions about people with low vitamin D levels.

Capsaicinoid or capsinoid supplementation showed a favorable signal for resistance-exercise performance after acute use. In aerobic exercise, time to exhaustion improved, but the pooled overall performance result was not statistically significant. Longer-term evidence was limited and inconsistent, so the review does not establish a dependable training benefit or a regimen to follow.

Keep in mind: The abstract does not report comparison treatments, supplement doses, adverse events, or the exact duration of the included studies. Sparse chronic evidence limits conclusions about sustained changes in performance.

This review describes how proanthocyanidins, a class of plant compounds, might influence processes involved in nervous-system disease. Its main support is described as preclinical, and it also discusses gut metabolism and delivery systems. The abstract provides no patient-level results showing that taking these compounds prevents disease, improves symptoms, or changes clinical outcomes.

Keep in mind: This abstract-based overview lacks study-selection details, clinical sample sizes, treatment comparisons, and quantified outcomes. Although clinical research is mentioned, its findings cannot be assessed from the supplied abstract.

Vitamin D was linked to lower values for an insulin-resistance index, fasting insulin, an inflammatory marker, and total testosterone in patients with PCOS. Several other measurements showed no statistically significant differences. These results concern laboratory markers; the abstract does not establish improvements in symptoms, fertility, or longer-term health, and it does not identify an optimal dose.

Keep in mind: The abstract does not report participant totals, treatment duration, doses, or study-level bias assessments. This abstract-based summary therefore cannot establish how clinically meaningful or dependable the marker changes are.

Evidence for nutritional supplements in cancer supportive care varied by supplement, side effect and patient group. A few findings reached moderate certainty, but most evidence was low or very low certainty, and some supplements had reported harms. The review does not support broad claims that supplements reliably relieve treatment side effects or improve cancer outcomes.

Keep in mind: Almost all included reviews had low or critically low methodological quality. The authors also called for research on whether supplements affect standard treatment effectiveness, which this abstract does not resolve.

Adding the studied fatty acid supplement to standardized psychotherapy did not outperform placebo for young people with major depression. Depression scores improved similarly in both groups, and secondary outcomes showed no significant between-group differences. The result does not establish equivalence, but it provides no evidence of an added benefit under these trial conditions.

Keep in mind: This abstract-based summary concerns a specific formulation added to psychotherapy for youths with major depression. It cannot establish effects of other formulations, use without psychotherapy or outcomes in other populations.

Supplementation changed where EPA and DHA appeared among fats circulating in the blood, and increased related compounds called oxylipins compared with corn oil. These results describe biochemical changes. They do not establish that symptoms improved or disease risk fell, and the authors call for further research connecting these changes with markers of inflammation.

Keep in mind: This abstract-based explanation covers an exploratory analysis using available samples, mostly from women. The abstract reports biochemical outcomes and does not establish clinical benefit or explain how representative the available samples were.

The review reported better bench press and squat performance with whey supplementation. Neither whey nor soy showed a statistically significant effect on lean body mass. These separate results do not establish that whey works better than soy, and the lean mass findings should not be read as proof that either supplement has no effect.

Keep in mind: Comparison groups, intervention durations and units for the strength differences are absent from the abstract. Those omissions limit interpretation of the reported gains and prevent a clear judgment of their practical size.

In this trial, saffron supplementation improved several reported symptom and quality-of-life measures compared with placebo and lowered C-reactive protein, an inflammation marker. The oxidative-stress marker malondialdehyde did not show a statistically significant between-group change. These results concern people with Parkinson's disease and do not establish slower disease progression or a general benefit for healthy adults.

Keep in mind: Symptom scales and clinically meaningful thresholds are not explained in the abstract. The short observation period and absence of observed side effects do not establish longer-term safety or effects on disease progression.

The trial found no clear delay in prostate-cancer progression or the start of active treatment with vitamin D versus placebo in men under surveillance. Some blood-cell markers declined, but these changes do not demonstrate improved cancer outcomes. The results also do not prove that the treatments are equivalent or rule out smaller effects.

Keep in mind: The abstract supplies no survival effect sizes or confidence intervals and does not specify survival follow-up duration. That limits assessment of how much benefit or harm remains compatible with the findings.

Vitamin D and calcium showed no statistically clear overall bone-density improvement. Participants with initial vitamin D insufficiency had a favorable lumbar-spine result. Evidence that effects differed by starting vitamin D status was statistically significant for the lumbar spine, but not for the whole-body measure excluding the head. This finding does not establish benefit for all adolescents with HIV.

Keep in mind: The overall adjusted estimates are internally inconsistent with their confidence intervals, so this abstract-based brief reports the authors' overall conclusion qualitatively. Muscle outcomes mentioned in the aim are not reported.

Supplementation produced a modest average reduction in systolic blood pressure, the study's clearest overall result. The pooled diastolic estimate was uncertain and did not reach statistical significance. These findings apply to adults with prediabetes or diabetes in the included trials; they do not establish that supplementation prevents cardiovascular events or identify an optimal dose.

Keep in mind: This abstract-based summary lacks treatment durations and details of the control regimens. Diastolic findings varied substantially across studies, and subgroup results do not establish that a particular formulation or dose is superior.

In this exploratory reanalysis, changes in muscle strength, size and physical function did not differ significantly across the age, sex or BMI subgroups. That result does not establish equal benefit for everyone. A separate electrical muscle measure suggested a sex-related difference, but it is not evidence of a larger strength benefit in men.

Keep in mind: Exploratory subgroup analyses involved a modest sample. The abstract omits subgroup effect sizes and confidence intervals for strength, size and physical function, so it cannot show whether meaningful response differences were excluded.

Across the included trials, sumac supplements improved blood sugar and blood lipid measures compared with placebo. Other cardiovascular risk factors did not show statistically significant changes, including inflammatory markers. These are findings about risk markers over a short study period; the abstract does not report whether supplementation prevented heart attacks or other cardiovascular events.

Keep in mind: The abstract gives no individual outcome estimates, confidence intervals, doses or participant health profiles. It therefore cannot establish the size or clinical importance of the reported changes, or identify an optimal dose or duration.

Nattokinase did not produce a statistically significant improvement in global cognition compared with placebo in this trial of people with symptom-free arterial narrowing. An exploratory analysis suggested a benefit in visuospatial function, a narrower cognitive domain. That signal should be read alongside the main null result, rather than as evidence of broad cognitive enhancement.

Keep in mind: Only 88 participants completed follow-up while taking the assigned treatment as required. The visuospatial finding was exploratory, and the abstract does not establish its clinical importance or whether any benefit persists beyond the study.

The pooled estimate favored berberine for body weight, with a modest average difference from control groups. Body mass index also fell, while waist-to-hip ratio did not show a statistically significant reduction. These findings concern body measurements; the abstract does not establish improvements in obesity-related illness, long-term weight maintenance or the experience of individual participants.

Keep in mind: The authors highlight problems with preparation reporting and common trial biases. The waist-circumference result is reported with an unclear unit, so its numerical estimate is omitted here.

Across the included studies, nutraceutical interventions were associated with lower fasting insulin and luteinizing hormone, alongside higher sex-hormone-binding globulin. These are laboratory measurements. Results for menstrual bleeding and ovarian follicle count were inconsistent, so the abstract does not establish more predictable periods or improved fertility, nor does it identify a reliably superior supplement.

Keep in mind: The authors identify differences between studies and variable methodological quality. The abstract does not report treatment durations, comparator details or evidence-certainty ratings, limiting interpretation of the pooled laboratory results.

The pooled trials reported reductions in several cardiometabolic markers with taurine, including blood pressure, glucose and cholesterol measures. These results describe measured risk factors, not demonstrated prevention of disease. Although the authors suggest possible future disease benefits, the abstract does not report heart attacks, strokes or new diagnoses as outcomes of supplementation.

Keep in mind: Participant health profiles, control treatments and adverse-event findings are absent from the abstract. These omissions limit how confidently its marker results can be applied to particular groups.

The pooled trials did not show a statistically clear anxiety benefit from probiotics over placebo. A signal appeared among participants with neurodevelopmental diagnoses, particularly autism spectrum disorder, but the authors considered the evidence insufficient. This does not establish a benefit for all children and adolescents, and the overall result does not rule out an effect.

Keep in mind: The diagnosis-specific evidence included only 3 autism trials and 2 ADHD trials. The abstract does not report treatment durations or probiotic product details, limiting how specifically the findings can be interpreted.

In people with chronic spinal cord injury, 12 months of vitamin D supplementation did not produce a detected change in bone mineral density. This finding concerns a secondary outcome in a specific clinical population. It leaves uncertainty about the size of any possible effect and does not establish that supplementation is ineffective in every setting.

Keep in mind: The abstract provides no bone-density effect estimates or confidence intervals, limiting assessment of the range of effects compatible with the reported results.

The review did not find consistent evidence that probiotics improve depression or schizophrenia. Schizophrenia symptom-score reductions did not differ significantly from placebo. Another pooled comparison reached statistical significance, but the abstract does not identify its outcome or report its effect size. That mixed reporting cannot establish a dependable psychiatric benefit.

Keep in mind: This abstract-based account cannot resolve the unspecified pooled result. Considerable variation across trials and missing details on probiotic preparations, follow-up and outcome-specific estimates limit interpretation. The nonsignificant schizophrenia comparison does not prove that probiotics have no effect.

This article examines why vitamin D research has not settled basic questions about deficiency and disease prevention. The author argues that many trials enrolled people who already had adequate levels and were poorly suited to detect small effects. These are arguments about interpreting and designing research, rather than new trial evidence of benefit.

Keep in mind: The abstract provides no systematic search methods, study-level results or pooled effect estimates. Its broad claims about previous trials and possible benefits cannot be independently assessed from this summary.